OpGen

OpGen Graham Number

The Graham Number of OpGen (OPGN) as of Oct 29, 2026 is 12.87 USD. In the previous year, Graham Number was 4.41 USD — a change of 191.56% (higher).

Graham Number

12.87USD

YoY

191.56%

Last updated:

Graham Number of OpGen is 2025 12.87 USD. Graham Number of OpGen was 2024 4.41 USD. It decreases by 191.56% higher compared to the previous year.

The OpGen Graham Number history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Graham Number
Date
Graham Number
Jan 1, 2024
4.41 USD
Jan 1, 2025
12.87 USD
The OpGen Graham Number history
YEARGraham NumberYoY
12.87USD+191.56%
4.41USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Graham Number of OpGen is 12.87 USD in 2025.

On Eulerpool you can find the complete historical development of Graham Number OpGen since 2006 – with annual values, charts, and detailed analysis.

The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — OpGen

All Key Metrics — OpGen